Australian vaccine developer claims 10 years are needed to monitor side-effects
- Thread starter Phil C. McNasty
- Start date
The MRNA vaccines will be viewed by future generations, as one of the greatest scientific achievements in history.
COVID-19 vaccine developer facing sack after refusing jabs because he's had his own
www.abc.net.au
Researcher refuses vaccines because he's had a dose of his own COVID-19 jab
An Adelaide medical researcher who has developed and been administered with his own COVID-19 vaccine says he is facing the sack because of his refusal to get one of the TGA-approved jabs.
www.abc.net.au
Phil states that he has been telling us all along that it will take "at least 10 years to monitor the side effects".
Wonder how many times "all along" is?
Good luck. I've asked 5 times. All of a sudden, Phil does not have such a big mouth. He knows that he's cornered himself.
Hmm.... With the survivability north of 99% how in the name of Zeus will Covid run.out of hosts? Have we gone completely bonkers over this?
Mice =/= human beingsSo what would be a reasonable amount of time to study mRNA vaccines? 10 years? How about 13?
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA - PubMed
Vaccination against tumor antigens has been shown to be a safe and efficacious prophylactic and therapeutic antitumor treatment in many animal models. Clinical studies in humans indicate that specific immunotherapy can also result in clinical benefits. The active pharmaceutical ingredient in...pubmed.ncbi.nlm.nih.gov
And the first mRNA vaccine trials on mice was in 1993
And if you knew anything about science you'd know that protein vaccines are proven to be safe because they have been around for a very long time.
Thats why as soon as the Novavax vaccine is approved I'm switching to that one, because it's a protein vaccine and not an mRNA vaccine
Last edited:
I don't understand why this is so hard to believe. It is not like anyone is saying there IS going to be side effects, just that it will take up to 10 years to see. Makes completely logical sense.
I figured this when I took the vaccine. I fully acknowledged I was taking something found to be safe now but could have effects later.
Why is this an issue?
I figured this when I took the vaccine. I fully acknowledged I was taking something found to be safe now but could have effects later.
Why is this an issue?
Novavax vaccine has already been approved by the CDC for air travel in the US, so its looking good right now
Because there are still chickens out there willing to seize on any pretense to keep some nasty Dr. or nurse (and maybe somebody from a different racial or ethnic group -horrors!) from sticking that sharp needle into their privileged arms...
So covering it up is the better way to gain their trust?????? LOL
The truth is the truth. You can't hide that and you can't deny that.
Here's a good article on mRNA vaccines vs. protein vaccines:
www.chemistryworld.com
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
There are no protein-based vaccines among the nine candidates in phase 3 clinical trials for Covid-19. The fastest efforts so far rely on inactivated virus, nucleic acids or vector-based strategies.
Yet protein-based vaccines are well established, and will likely work. The most advanced for Covid-19 is from Novavax, based on the entire Sars-CoV-2 spike protein plus an immune system-activating adjuvant. However, perfecting a production system for the spike protein is challenging.
The lead vaccines, which have garnered the lion’s share of attention and funding, were not selected because they’re the best, says Nikolai Petrovsky of Flinders University in Adelaide, Australia. ‘They were just the technologies that were sitting there back in February that governments jumped on,’ he says. Faster is not necessarily better, he warns.
Most protein-based vaccines for Covid-19 employ recombinant versions of the spike protein (or parts of it), which tutors the immune system against wild virus. This works with an adjuvant, a compound that puts frontline immune cells on battle alert, thus mustering a robust immune response to the protein antigen.
In August, Novavax published positive phase 1 data. ‘The Novavax vaccine is looking outstanding,’ says Florian Krammer from the Icahn School of Medicine in New York City, US. ‘They have – so far – the highest neutralising antibody titres I have seen.’ The vaccine also provided sterilising immunity (which stops the virus replicating inside host cells) in non-human primates. Novavax has begun enrolling 2900 volunteers for a phase 2b trial in South Africa.
Protein-based vaccines are going to bulldoze their way to the front, because they are going to be so much better.
Companies also already know how to manufacture recombinant proteins at scale. ‘This is established technology that has been around for decades,’ says Peter Hotez, vaccine scientist at Baylor College of Medicine in Houston, US. ‘They have an excellent record for safety and effectiveness.’ Krammer adds that there is also no risk of immunity to the viral vector reducing the effectiveness of booster doses.
Protein-based Covid-19 vaccines could overshadow rivals
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
www.chemistryworld.com
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
There are no protein-based vaccines among the nine candidates in phase 3 clinical trials for Covid-19. The fastest efforts so far rely on inactivated virus, nucleic acids or vector-based strategies.
Yet protein-based vaccines are well established, and will likely work. The most advanced for Covid-19 is from Novavax, based on the entire Sars-CoV-2 spike protein plus an immune system-activating adjuvant. However, perfecting a production system for the spike protein is challenging.
The lead vaccines, which have garnered the lion’s share of attention and funding, were not selected because they’re the best, says Nikolai Petrovsky of Flinders University in Adelaide, Australia. ‘They were just the technologies that were sitting there back in February that governments jumped on,’ he says. Faster is not necessarily better, he warns.
Most protein-based vaccines for Covid-19 employ recombinant versions of the spike protein (or parts of it), which tutors the immune system against wild virus. This works with an adjuvant, a compound that puts frontline immune cells on battle alert, thus mustering a robust immune response to the protein antigen.
In August, Novavax published positive phase 1 data. ‘The Novavax vaccine is looking outstanding,’ says Florian Krammer from the Icahn School of Medicine in New York City, US. ‘They have – so far – the highest neutralising antibody titres I have seen.’ The vaccine also provided sterilising immunity (which stops the virus replicating inside host cells) in non-human primates. Novavax has begun enrolling 2900 volunteers for a phase 2b trial in South Africa.
Protein-based vaccines are going to bulldoze their way to the front, because they are going to be so much better.
Companies also already know how to manufacture recombinant proteins at scale. ‘This is established technology that has been around for decades,’ says Peter Hotez, vaccine scientist at Baylor College of Medicine in Houston, US. ‘They have an excellent record for safety and effectiveness.’ Krammer adds that there is also no risk of immunity to the viral vector reducing the effectiveness of booster doses.
Last edited:
Interesting indeed.Here's a good article on mRNA vaccines vs. protein vaccines:
Protein-based Covid-19 vaccines could overshadow rivals
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
There are no protein-based vaccines among the nine candidates in phase 3 clinical trials for Covid-19. The fastest efforts so far rely on inactivated virus, nucleic acids or vector-based strategies.
Yet protein-based vaccines are well established, and will likely work. The most advanced for Covid-19 is from Novavax, based on the entire Sars-CoV-2 spike protein plus an immune system-activating adjuvant. However, perfecting a production system for the spike protein is challenging.
The lead vaccines, which have garnered the lion’s share of attention and funding, were not selected because they’re the best, says Nikolai Petrovsky of Flinders University in Adelaide, Australia. ‘They were just the technologies that were sitting there back in February that governments jumped on,’ he says. Faster is not necessarily better, he warns.
Most protein-based vaccines for Covid-19 employ recombinant versions of the spike protein (or parts of it), which tutors the immune system against wild virus. This works with an adjuvant, a compound that puts frontline immune cells on battle alert, thus mustering a robust immune response to the protein antigen.
In August, Novavax published positive phase 1 data. ‘The Novavax vaccine is looking outstanding,’ says Florian Krammer from the Icahn School of Medicine in New York City, US. ‘They have – so far – the highest neutralising antibody titres I have seen.’ The vaccine also provided sterilising immunity (which stops the virus replicating inside host cells) in non-human primates. Novavax has begun enrolling 2900 volunteers for a phase 2b trial in South Africa.
Protein-based vaccines are going to bulldoze their way to the front, because they are going to be so much better.
Companies also already know how to manufacture recombinant proteins at scale. ‘This is established technology that has been around for decades,’ says Peter Hotez, vaccine scientist at Baylor College of Medicine in Houston, US. ‘They have an excellent record for safety and effectiveness.’ Krammer adds that there is also no risk of immunity to the viral vector reducing the effectiveness of booster doses.
But important key point. Novavax is enrolling clinical trial 2. They are late to the game. By the time they finish trial 3 they may end up having the most efficient vaccine but will we need it as much.
Current mrna vaccines have saved millions of lives already.
mrna technology is on a great path for a oncology cancer vaccine. If they succeed it will prevent millions from hard chemotherapy and nasty cancer treatment.
covid pills may be the game changer even before Novovax is out... You get tested positive you take the pill. Bingo! (a bit like chlamydiae or gono
)
Quite possibly it is already here but has been severely maligned in a attempt for greater profits. 3 CL protease inhibitors could be game changers.covid pills may be the game changer even before Novovax is out... You get tested positive you take the pill. Bingo! (a bit like chlamydiae or gono
This is a short video explaining why.
Phil is so chicken shit to answer my question that he has now put me on ignore.
Nothing more needs to be said. He knows that he's talking out of his ass and I nailed him. LOL
Hey Phil. How many years of testing is "long term"?
How protein-based COVID vaccines could change the pandemic
www.nature.com
How protein-based COVID vaccines could change the pandemic
Jabs from Novavax and other biotech firms are coming. Scientists say they have a lot to offer.
www.nature.com
Were you incapable of reading where the study talks about HUMAN TRIALS?
But you have convinced me about the 'we don't know' line. I'm moving to a larger place just in case our alien overlords show up and need a place to stay.
13 years since human trials seems a pretty long time to me. and if you knew anything about science, you'd understand that conclusions rely on evidence.
